A new study in BJU International has shown the importance of waiting at least 3 weeks after initiation of androgen deprivation therapy (ADT) until initiation of docetaxel chemotherapy in the treatment of men with newly diagnosed, metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, chemotherapy, deprivation, docetaxel, hormone-sensitive, metastatic, neutropenia, risk, timing | 2 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 